“…MET being dihydrofolate inhibitor is extensively used for the treatment of various malignancies, such as lymphoma, leukemia, and sarcoma . Indeed MET exhibits therapeutic effects on a variety of cancer cells with overexpressed folate receptors. − MET has been popularly used in breast, lung, cervical, and skin cancers. − However, its limited water solubility (0.1 mg/mL) results in poor bioavailability . In order to increase drug solubility, minimize side effects, and thereby enhance the therapeutic efficacy of MET, researchers have employed nanoparticle-based drug delivery systems (DDS), including liposomes, micelles, dendrimers, polymeric nanoparticles, and solid lipid nanoparticles (SLNs). − MET-loaded polymeric micelles have been proposed in the literature for the treatment of RA. , In recent literature, polymer-based nanoparticles have been utilized for the formulation of MET. , More recently, Dang and co-workers have successfully formulated a folic acid-targeted and dual stimuli-responsive polymer-based nanocarrier for MET delivery for the treatment of RA .…”